about
Next-generation prognostic assessment for diffuse large B-cell lymphomaNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewLoss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent updateImmunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacyLenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.Panobinostat in lymphoid and myeloid malignancies.A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trialDiffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?Peripheral blood lymphocyte/monocyte ratio at the time of first relapse predicts outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.The long non-coding RNA NONHSAG026900 predicts prognosis as a favorable biomarker in patients with diffuse large B-cell lymphoma.Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.EP300 single nucleotide polymorphism rs20551 correlates with prolonged overall survival in diffuse large B cell lymphoma patients treated with R-CHOP.Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.Salvage therapy with mitoxantrone, etoposide, bleomycin and dexamethasone for refractory or relapsed aggressive non-Hodgkin's lymphoma patients with a poor performance status or comorbidity.Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma.Inhibition of human diffuse large B-cell lymphoma growth by JC polyomavirus-like particles delivering a suicide geneAssessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.FOXP1 potentiates Wnt/β-catenin signaling in diffuse large B cell lymphoma.Does the presence of tumor-induced cortical bone destruction at CT have any prognostic value in newly diagnosed diffuse large B-cell lymphoma?Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosisSNS01-T modulation of eIF5A inhibits B-cell cancer progression and synergizes with bortezomib and lenalidomide.miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients.Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphomaVDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma.Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma.Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphomaUCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma.Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL.Prediction of survival of diffuse large B-cell lymphoma patients via the expression of three inflammatory genes.25 Years Old Women With Inflammatory Low Back Pain.Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cellsIntrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signalingDiffuse Large B-Cell Lymphoma in the Era of Precision Oncology: How Imaging Is Helpful.Complete response to azacitidine priming and nab-paclitaxel in non-Hodgkin lymphoma resistant to biochemotherapy.Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers.
P2860
Q26796428-D3E8D2F6-913D-4278-888D-CFF09514FC17Q27304386-ABD99BE4-E62F-44E4-9D7F-B1074A4BC853Q27853399-30A95903-6F0F-44B6-9C2C-382BA43BF90CQ28078869-5F890DED-6514-482E-89BF-6611869E260CQ30659342-40583C1A-0F44-4245-A7CD-B601300137BAQ33408772-208D38EB-10D9-4ED0-8C6C-81A3569A9853Q33408889-FDEF0DD0-BC87-4DF8-8FD1-1D677EAE3779Q33409608-3C034FF4-F0DA-4440-851D-644A55DC29BBQ33431267-152DDADD-58A3-46E0-89B5-16A34E94EBCEQ33622342-42399B79-2F74-4321-ACD5-9D26449AAAE0Q33662640-16E91BC6-621E-4453-AC09-3B270F3990BBQ33798371-D44AE469-EF37-416F-A0B8-7F06BE0B2D7DQ33851726-F3AAFFB9-AFA3-4BC6-AC10-FCEBA5A10B7BQ33909338-8EB7CF0F-4A4B-4F65-9AD3-E8953410D867Q34041792-D4298034-6EF9-4801-A7EA-3B641BA0E482Q34293322-6B7B602F-A720-4362-B566-7517DCB5C79FQ34365673-6F6F7194-C250-468D-8DE0-09504A2547AEQ34459849-E0EB9751-75E1-42A3-9079-3C9226F3B26FQ34543066-3E3C0D0C-70D8-425C-B698-F1BF17DFF64BQ34860750-00CE72C5-2BD4-455D-88B6-9EA49348BF52Q35167200-10DA92FA-A9E6-462D-B1F1-FB79332C0DB4Q35187833-83E9773D-A995-4D2D-A1DD-E01E9A63F5C4Q35419876-06D73968-78E6-42A0-AF45-8395167CB878Q35618595-F6B8AD2B-EBFD-4D04-9857-548D2C23CE31Q35739550-6BC5927C-106D-4F43-A628-491074A931F6Q35742364-1D2F3FE5-6726-42DD-95B7-544848A4BB61Q35896877-1BA10C00-08CA-49A3-A0B0-6F040685698FQ35920657-EF768B3D-A0AD-4DD4-B84D-FDAA6CCC7BE5Q35986409-EE101576-81F4-4712-9171-7E1772A88BB7Q36710788-D411F026-784C-44AB-A02C-3B711CB2EA93Q36727872-9FAC4DB1-6C52-4DFF-A22F-ED813F2734F1Q36897012-D2022767-1423-4805-BBEC-8C8C36DCDE4AQ37148950-9AE2E022-3DFB-40B0-9670-266785476383Q37229557-2F726A6E-B38A-4193-9CBF-30F0753E7719Q37362929-F793ABB0-F530-4474-B73B-A2AD57B26663Q37437166-7657EFC2-F74C-46F6-8EC7-52AFED47FBB3Q37589543-D89BDE32-0586-416A-93ED-11EF759D40CEQ37594238-AD8A7D26-B539-4030-8044-4537805CC3EFQ37613336-D0A85DD6-CE3C-441A-96D3-AF0D6692546DQ37621025-F7C5967F-AFC0-4487-A881-A798D2E1A155
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Relapsed/refractory diffuse large B-cell lymphoma.
@en
Relapsed/refractory diffuse large B-cell lymphoma.
@nl
type
label
Relapsed/refractory diffuse large B-cell lymphoma.
@en
Relapsed/refractory diffuse large B-cell lymphoma.
@nl
prefLabel
Relapsed/refractory diffuse large B-cell lymphoma.
@en
Relapsed/refractory diffuse large B-cell lymphoma.
@nl
P1476
Relapsed/refractory diffuse large B-cell lymphoma.
@en
P2093
Jonathan W Friedberg
P304
P356
10.1182/ASHEDUCATION-2011.1.498
P577
2011-01-01T00:00:00Z